FY2025 EPS Estimates for AnaptysBio Boosted by HC Wainwright

AnaptysBio, Inc. (NASDAQ:ANAB) – HC Wainwright boosted their FY2025 earnings estimates for shares of AnaptysBio in a research note issued to investors on Tuesday, November 11th. HC Wainwright analyst E. Bodnar now forecasts that the biotechnology company will post earnings of ($3.15) per share for the year, up from their prior forecast of ($3.56). HC Wainwright currently has a “Buy” rating and a $52.00 target price on the stock. The consensus estimate for AnaptysBio’s current full-year earnings is ($6.08) per share. HC Wainwright also issued estimates for AnaptysBio’s Q4 2025 earnings at ($1.00) EPS, Q2 2026 earnings at ($0.40) EPS, FY2026 earnings at ($3.92) EPS, FY2027 earnings at ($7.64) EPS, FY2028 earnings at ($3.39) EPS and FY2029 earnings at ($1.13) EPS.

AnaptysBio (NASDAQ:ANAB) last posted its earnings results on Tuesday, November 4th. The biotechnology company reported $0.52 earnings per share for the quarter, topping analysts’ consensus estimates of ($1.06) by $1.58. The company had revenue of $76.32 million during the quarter, compared to analyst estimates of $15.83 million. AnaptysBio had a negative return on equity of 1,101.24% and a negative net margin of 49.94%.

Several other brokerages also recently weighed in on ANAB. Stifel Nicolaus increased their price target on shares of AnaptysBio from $55.00 to $80.00 and gave the stock a “buy” rating in a report on Wednesday, October 29th. Guggenheim upped their price objective on shares of AnaptysBio from $90.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Wells Fargo & Company raised their target price on shares of AnaptysBio from $51.00 to $81.00 and gave the stock an “overweight” rating in a report on Wednesday, November 5th. Weiss Ratings restated a “sell (d-)” rating on shares of AnaptysBio in a research report on Wednesday, October 8th. Finally, JPMorgan Chase & Co. upped their price target on shares of AnaptysBio from $42.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday, July 24th. One research analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $59.40.

AnaptysBio Stock Up 0.5%

NASDAQ:ANAB opened at $33.26 on Thursday. The stock has a market capitalization of $920.97 million, a price-to-earnings ratio of -11.79 and a beta of 0.16. AnaptysBio has a 52 week low of $12.21 and a 52 week high of $40.96. The firm has a 50 day moving average of $29.80 and a 200 day moving average of $25.03.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the business. Bank of New York Mellon Corp increased its position in shares of AnaptysBio by 7.1% during the first quarter. Bank of New York Mellon Corp now owns 61,207 shares of the biotechnology company’s stock worth $1,138,000 after acquiring an additional 4,038 shares during the period. Victory Capital Management Inc. boosted its holdings in AnaptysBio by 21.5% in the first quarter. Victory Capital Management Inc. now owns 406,430 shares of the biotechnology company’s stock valued at $7,556,000 after purchasing an additional 71,980 shares during the period. Skandinaviska Enskilda Banken AB publ acquired a new position in AnaptysBio during the 1st quarter worth $623,000. Corton Capital Inc. purchased a new stake in AnaptysBio during the 1st quarter worth about $199,000. Finally, US Bancorp DE raised its position in AnaptysBio by 126.5% in the 1st quarter. US Bancorp DE now owns 1,753 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 979 shares in the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.